Ogeda

Ogeda (formerly named Euroscreen) is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women's health disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. Ogeda is backed by leading investors, including Vealius Biocapital II SA Sicar, Fund+ NV, SRIW SA, Capricorn Health-Tech Fund NVHT fund, BNP Paribas Fortis Private Equity Management SA. For more information, please visit: www.ogeda.com

Ogeda headquartered in Europe, operates in the Biotechnology, Health Care, Pharmaceutical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $990.1M in funding across 32 round(s). With a team of 11-50 employees, Ogeda is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Ogeda, raised $17.9M. Discover more about their projects, partnerships, and impact on our platform.